VivoSeq
Oncology

Malignant Brain Tumors

0

Pipeline Programs↗

5

Active Trials↗

3

Companies Involved↗

Malignant Brain Tumors is an early-stage landscape with 0 programs across 3 companies. The most active players are Teva, ABM Therapeutics Shanghai Company Limited, Haisco Pharmaceutical Group Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

55/100

Attrition Rate

32/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Teva logo

Teva

0 programs

PreclinicalA

ABM Therapeutics Shanghai Company Limited

0 programs

PreclinicalHaisco Pharmaceutical Group Co., Ltd. logo

Haisco Pharmaceutical Group Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

28

clinical trials

Completed11 · 39%
Terminated6 · 21%
Recruiting4 · 14%
Unknown status3 · 11%
Withdrawn3 · 11%
Active, not recruiting1 · 4%

Clinical Trials

Trial Activity

28 trials

Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
Recruiting·EEmory University·Phase 1·NCT06624371·18 enrolled
Phase I Study of HSK42360 in Malignant Brain Tumors With BRAF V600 Mutation
Recruiting·Haisco Pharmaceutical Group Co., Ltd. logoHaisco Pharmaceutical Group Co., Ltd.·Phase 1·NCT07158710·159 enrolled
Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors
Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT06914479·11 enrolled
A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Malignant Brain Tumors
Recruiting·—·Phase 1/2·NCT07003139·10 enrolled
A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT03465618·17 enrolled
PET/CT Imaging of Malignant Brain Tumors With 124I-NM404
Completed·UUniversity of Wisconsin, Madison·N/A·NCT01516905·19 enrolled
Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors
Completed·UUniversity of California, San Francisco·Phase 1·NCT05169944·13 enrolled
Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Completed·NNewLink Genetics Corporation·Phase 1·NCT02502708·81 enrolled
Antineoplaston Therapy in Treating Patients With Primary Malignant Brain Tumors
Completed·—·Phase 2·NCT00003475·40 enrolled
WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors
Completed·EEmory University·Phase 1·NCT04334863·10 enrolled
Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
Completed·Teva logoTeva·Phase 2·NCT00104091·56 enrolled
GW572016 to Treat Recurrent Malignant Brain Tumors
Completed·National Cancer Institute (NCI)·Phase 2·NCT00107003·9 enrolled
Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors
Completed·Teva logoTeva·Phase 2·NCT00071539·56 enrolled
Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors
Completed·NNYU Langone Health·Phase 2·NCT00528437·46 enrolled
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Completed·NNewLink Genetics Corporation·Phase 1/2·NCT02052648·160 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)